AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$VSTM

Calkins Daniel sold $424 of VSTM

Calkins Daniel (Chief Financial Officer) sold 55 shares of Verastem, Inc. (VSTM) at $7.70 on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Calkins Daniel
Published Sep 24, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The transaction is a standard liquidity event with minimal market impact.

02

Market read

Low relevance; typical insider sell with no material effect on stock price.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 2/10Novelty 4/10Timing: filed Sep 23, 2026

Background

Form 4 filings disclose insider transactions; this is a routine 10b5‑1 sale by Verastem's CFO.

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

CFO Daniel Calkins sold 55 shares for $423.50 via a 10b5‑1 plan on Sep 21, 2026.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is trivial relative to holdings and market cap; typical pre‑arranged sale.

Market effects

Sector

None; insider sale does not affect biotech sector outlook.

Regional

None; limited to Verastem shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal confidence issues; monitor for further disposals.

Key entities

  • Company
    Verastem, Inc.

    Biotech firm listed on Nasdaq (VSTM).

  • Executive
    Daniel Calkins

    Chief Financial Officer of Verastem.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

OCT 5
$VSTMMedAI 8/10

Verastem shares get Buy rating reiterated by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

investing.com2 min
OCT 2
$VSTMHighAI 9/10

Verastem presents new data on ovarian cancer drug combination

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

investing.com2 min
AUG 20
$VSTMHighAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

aol.com3 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min